Global Hospital Injectable Drugs Market Size, Share, Trends and Forecast 2022-2030

Injectables refer to drug delivery system which acts as an alternative to oral drugs. As injectables are rapidly inserted into the human body using a syringe, they bypass the first-pass metabolism. In tablet form, some of the drugs become ineffective as they get dismantled in the stomach owing to the digestive enzymes. Generic injectables are pharmaceutical drugs that are bio-equivalent of a branded injectable in terms of dosage, strength, performance, intended use, side-effects and route of administration.
Industry Insights

The global Hospital Injectable Drugs market size is projected to reach US$ 56330 million by 2028, from US$ 40410 million in 2021, at a CAGR of 4.8% during 2022-2028.

In 2019, North America held the main share in global hospital injectable drugs market,with the propotion of 35%,Europe followed loosely ,at the propotion of 33%.

Hospira (Pfizer Inc.) occupied the biggest global hospital injectable drugs market share(13%), Fresenius Kabi followed closely at the propotion of 13%, Baxter and Sichuan Kelun Pharmaceutical also played a virtal role in the market.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Hospital Injectable Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Hospital Injectable Drugs market in terms of revenue.

Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Hospital Injectable Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Hospital Injectable Drugs market.

Impact of Covid-19 Outbreak

This section of the report has explored the overall status of the Covid scenario and has offered valuable insights into the changes in supply chain disruption, fluctuations in demand, etc. The analysts have also focused on the key measures that the companies are opting to withstand the harsh scenario.

Segmental Analysis

The report has been segmented into product and application segments. The researchers have documented all the products present today in the Hospital Injectable Drugs market. They have also shed light on the new product innovations and launches by the key players. In the segmental analysis, the analysts have provided revenue forecast figures based on type and application for the period 2017-2028. They have also discussed about the growth rate and potential of each segment for the period 2017-2028.

Hospital Injectable Drugs Breakdown Data by Type

Generic Sterile Injectables

Sterile Intravenous (IV) Solutions

Hospital Injectable Drugs Breakdown Data by Application

Oncology

Anesthesia

Anti-Infectives

Parenteral Nutrition

Cardiovascular Diseases

Regional Analysis

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

Competitive Landscape

This segment focuses on the key players operating in the industry. It underlines all the current and future activities by the prominent manufacturers. By understanding various initiatives being taken up by different players, readers will gain the ability to settle on correct business choices. The authors of the report have provided accurate revenue figures of the companies for the period 2017-2022. The clients are sure to gain the upper hand once they get hold of this report. Key players studied in the research report include:

Hospira (Pfizer Inc.)

Baxter

Fresenius Kabi

Sandoz (Novartis)

Hikma Pharmaceuticals PLC

Dr. Reddy's Laboratories Ltd

Grifols

Nichi-Iko Group (Sagent)

Teva Pharmaceutical

Otsuka

B.Braun

JW Life Science

Auromedics

Sanofi

Gland Pharma

Endo International PLC

Sichuan Kelun Pharmaceutical

Cisen Pharmaceutical

Shijiazhuang No. 4 Pharmaceutical

Shandong Hualu Pharmaceutical

CR Double-Crane

1 Report Overview
1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Hospital Injectable Drugs Market Size Growth Rate by Type: 2017 VS 2021 VS 2028

1.2.2 Generic Sterile Injectables

1.2.3 Sterile Intravenous (IV) Solutions

1.3 Market by Application

1.3.1 Global Hospital Injectable Drugs Market Share by Application: 2017 VS 2021 VS 2028

1.3.2 Oncology

1.3.3 Anesthesia

1.3.4 Anti-Infectives

1.3.5 Parenteral Nutrition

1.3.6 Cardiovascular Diseases

1.4 Study Objectives

1.5 Years Considered

2 Global Growth Trends

2.1 Global Hospital Injectable Drugs Market Perspective (2017-2028)

2.2 Hospital Injectable Drugs Growth Trends by Region

2.2.1 Hospital Injectable Drugs Market Size by Region: 2017 VS 2021 VS 2028

2.2.2 Hospital Injectable Drugs Historic Market Size by Region (2017-2022)

2.2.3 Hospital Injectable Drugs Forecasted Market Size by Region (2023-2028)

2.3 Hospital Injectable Drugs Market Dynamics

2.3.1 Hospital Injectable Drugs Industry Trends

2.3.2 Hospital Injectable Drugs Market Drivers

2.3.3 Hospital Injectable Drugs Market Challenges

2.3.4 Hospital Injectable Drugs Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Hospital Injectable Drugs Players by Revenue

3.1.1 Global Top Hospital Injectable Drugs Players by Revenue (2017-2022)

3.1.2 Global Hospital Injectable Drugs Revenue Market Share by Players (2017-2022)

3.2 Global Hospital Injectable Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Hospital Injectable Drugs Revenue

3.4 Global Hospital Injectable Drugs Market Concentration Ratio

3.4.1 Global Hospital Injectable Drugs Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Hospital Injectable Drugs Revenue in 2021

3.5 Hospital Injectable Drugs Key Players Head office and Area Served

3.6 Key Players Hospital Injectable Drugs Product Solution and Service

3.7 Date of Enter into Hospital Injectable Drugs Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Hospital Injectable Drugs Breakdown Data by Type

4.1 Global Hospital Injectable Drugs Historic Market Size by Type (2017-2022)

4.2 Global Hospital Injectable Drugs Forecasted Market Size by Type (2023-2028)

5 Hospital Injectable Drugs Breakdown Data by Application

5.1 Global Hospital Injectable Drugs Historic Market Size by Application (2017-2022)

5.2 Global Hospital Injectable Drugs Forecasted Market Size by Application (2023-2028)

6 North America

6.1 North America Hospital Injectable Drugs Market Size (2017-2028)

6.2 North America Hospital Injectable Drugs Market Size by Country (2017-2022)

6.3 North America Hospital Injectable Drugs Market Size by Country (2023-2028)

6.4 United States

6.5 Canada

7 Europe

7.1 Europe Hospital Injectable Drugs Market Size (2017-2028)

7.2 Europe Hospital Injectable Drugs Market Size by Country (2017-2022)

7.3 Europe Hospital Injectable Drugs Market Size by Country (2023-2028)

7.4 Germany

7.5 France

7.6 U.K.

7.7 Italy

7.8 Russia

7.9 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Hospital Injectable Drugs Market Size (2017-2028)

8.2 Asia-Pacific Hospital Injectable Drugs Market Size by Country (2017-2022)

8.3 Asia-Pacific Hospital Injectable Drugs Market Size by Country (2023-2028)

8.4 China

8.5 Japan

8.6 South Korea

8.7 Southeast Asia

8.8 India

8.9 Australia

9 Latin America

9.1 Latin America Hospital Injectable Drugs Market Size (2017-2028)

9.2 Latin America Hospital Injectable Drugs Market Size by Country (2017-2022)

9.3 Latin America Hospital Injectable Drugs Market Size by Country (2023-2028)

9.4 Mexico

9.5 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Hospital Injectable Drugs Market Size (2017-2028)

10.2 Middle East & Africa Hospital Injectable Drugs Market Size by Country (2017-2022)

10.3 Middle East & Africa Hospital Injectable Drugs Market Size by Country (2023-2028)

10.4 Turkey

10.5 Saudi Arabia

10.6 UAE

11 Key Players Profiles

11.1 Hospira (Pfizer Inc.)

11.1.1 Hospira (Pfizer Inc.) Company Detail

11.1.2 Hospira (Pfizer Inc.) Business Overview

11.1.3 Hospira (Pfizer Inc.) Hospital Injectable Drugs Introduction

11.1.4 Hospira (Pfizer Inc.) Revenue in Hospital Injectable Drugs Business (2017-2022)

11.1.5 Hospira (Pfizer Inc.) Recent Development

11.2 Baxter

11.2.1 Baxter Company Detail

11.2.2 Baxter Business Overview

11.2.3 Baxter Hospital Injectable Drugs Introduction

11.2.4 Baxter Revenue in Hospital Injectable Drugs Business (2017-2022)

11.2.5 Baxter Recent Development

11.3 Fresenius Kabi

11.3.1 Fresenius Kabi Company Detail

11.3.2 Fresenius Kabi Business Overview

11.3.3 Fresenius Kabi Hospital Injectable Drugs Introduction

11.3.4 Fresenius Kabi Revenue in Hospital Injectable Drugs Business (2017-2022)

11.3.5 Fresenius Kabi Recent Development

11.4 Sandoz (Novartis)

11.4.1 Sandoz (Novartis) Company Detail

11.4.2 Sandoz (Novartis) Business Overview

11.4.3 Sandoz (Novartis) Hospital Injectable Drugs Introduction

11.4.4 Sandoz (Novartis) Revenue in Hospital Injectable Drugs Business (2017-2022)

11.4.5 Sandoz (Novartis) Recent Development

11.5 Hikma Pharmaceuticals PLC

11.5.1 Hikma Pharmaceuticals PLC Company Detail

11.5.2 Hikma Pharmaceuticals PLC Business Overview

11.5.3 Hikma Pharmaceuticals PLC Hospital Injectable Drugs Introduction

11.5.4 Hikma Pharmaceuticals PLC Revenue in Hospital Injectable Drugs Business (2017-2022)

11.5.5 Hikma Pharmaceuticals PLC Recent Development

11.6 Dr. Reddy's Laboratories Ltd

11.6.1 Dr. Reddy's Laboratories Ltd Company Detail

11.6.2 Dr. Reddy's Laboratories Ltd Business Overview

11.6.3 Dr. Reddy's Laboratories Ltd Hospital Injectable Drugs Introduction

11.6.4 Dr. Reddy's Laboratories Ltd Revenue in Hospital Injectable Drugs Business (2017-2022)

11.6.5 Dr. Reddy's Laboratories Ltd Recent Development

11.7 Grifols

11.7.1 Grifols Company Detail

11.7.2 Grifols Business Overview

11.7.3 Grifols Hospital Injectable Drugs Introduction

11.7.4 Grifols Revenue in Hospital Injectable Drugs Business (2017-2022)

11.7.5 Grifols Recent Development

11.8 Nichi-Iko Group (Sagent)

11.8.1 Nichi-Iko Group (Sagent) Company Detail

11.8.2 Nichi-Iko Group (Sagent) Business Overview

11.8.3 Nichi-Iko Group (Sagent) Hospital Injectable Drugs Introduction

11.8.4 Nichi-Iko Group (Sagent) Revenue in Hospital Injectable Drugs Business (2017-2022)

11.8.5 Nichi-Iko Group (Sagent) Recent Development

11.9 Teva Pharmaceutical

11.9.1 Teva Pharmaceutical Company Detail

11.9.2 Teva Pharmaceutical Business Overview

11.9.3 Teva Pharmaceutical Hospital Injectable Drugs Introduction

11.9.4 Teva Pharmaceutical Revenue in Hospital Injectable Drugs Business (2017-2022)

11.9.5 Teva Pharmaceutical Recent Development

11.10 Otsuka

11.10.1 Otsuka Company Detail

11.10.2 Otsuka Business Overview

11.10.3 Otsuka Hospital Injectable Drugs Introduction

11.10.4 Otsuka Revenue in Hospital Injectable Drugs Business (2017-2022)

11.10.5 Otsuka Recent Development

11.11 B.Braun

11.11.1 B.Braun Company Detail

11.11.2 B.Braun Business Overview

11.11.3 B.Braun Hospital Injectable Drugs Introduction

11.11.4 B.Braun Revenue in Hospital Injectable Drugs Business (2017-2022)

11.11.5 B.Braun Recent Development

11.12 JW Life Science

11.12.1 JW Life Science Company Detail

11.12.2 JW Life Science Business Overview

11.12.3 JW Life Science Hospital Injectable Drugs Introduction

11.12.4 JW Life Science Revenue in Hospital Injectable Drugs Business (2017-2022)

11.12.5 JW Life Science Recent Development

11.13 Auromedics

11.13.1 Auromedics Company Detail

11.13.2 Auromedics Business Overview

11.13.3 Auromedics Hospital Injectable Drugs Introduction

11.13.4 Auromedics Revenue in Hospital Injectable Drugs Business (2017-2022)

11.13.5 Auromedics Recent Development

11.14 Sanofi

11.14.1 Sanofi Company Detail

11.14.2 Sanofi Business Overview

11.14.3 Sanofi Hospital Injectable Drugs Introduction

11.14.4 Sanofi Revenue in Hospital Injectable Drugs Business (2017-2022)

11.14.5 Sanofi Recent Development

11.15 Gland Pharma

11.15.1 Gland Pharma Company Detail

11.15.2 Gland Pharma Business Overview

11.15.3 Gland Pharma Hospital Injectable Drugs Introduction

11.15.4 Gland Pharma Revenue in Hospital Injectable Drugs Business (2017-2022)

11.15.5 Gland Pharma Recent Development

11.16 Endo International PLC

11.16.1 Endo International PLC Company Detail

11.16.2 Endo International PLC Business Overview

11.16.3 Endo International PLC Hospital Injectable Drugs Introduction

11.16.4 Endo International PLC Revenue in Hospital Injectable Drugs Business (2017-2022)

11.16.5 Endo International PLC Recent Development

11.17 Sichuan Kelun Pharmaceutical

11.17.1 Sichuan Kelun Pharmaceutical Company Detail

11.17.2 Sichuan Kelun Pharmaceutical Business Overview

11.17.3 Sichuan Kelun Pharmaceutical Hospital Injectable Drugs Introduction

11.17.4 Sichuan Kelun Pharmaceutical Revenue in Hospital Injectable Drugs Business (2017-2022)

11.17.5 Sichuan Kelun Pharmaceutical Recent Development

11.18 Cisen Pharmaceutical

11.18.1 Cisen Pharmaceutical Company Detail

11.18.2 Cisen Pharmaceutical Business Overview

11.18.3 Cisen Pharmaceutical Hospital Injectable Drugs Introduction

11.18.4 Cisen Pharmaceutical Revenue in Hospital Injectable Drugs Business (2017-2022)

11.18.5 Cisen Pharmaceutical Recent Development

11.19 Shijiazhuang No. 4 Pharmaceutical

11.19.1 Shijiazhuang No. 4 Pharmaceutical Company Detail

11.19.2 Shijiazhuang No. 4 Pharmaceutical Business Overview

11.19.3 Shijiazhuang No. 4 Pharmaceutical Hospital Injectable Drugs Introduction

11.19.4 Shijiazhuang No. 4 Pharmaceutical Revenue in Hospital Injectable Drugs Business (2017-2022)

11.19.5 Shijiazhuang No. 4 Pharmaceutical Recent Development

11.20 Shandong Hualu Pharmaceutical

11.20.1 Shandong Hualu Pharmaceutical Company Detail

11.20.2 Shandong Hualu Pharmaceutical Business Overview

11.20.3 Shandong Hualu Pharmaceutical Hospital Injectable Drugs Introduction

11.20.4 Shandong Hualu Pharmaceutical Revenue in Hospital Injectable Drugs Business (2017-2022)

11.20.5 Shandong Hualu Pharmaceutical Recent Development

11.21 CR Double-Crane

11.21.1 CR Double-Crane Company Detail

11.21.2 CR Double-Crane Business Overview

11.21.3 CR Double-Crane Hospital Injectable Drugs Introduction

11.21.4 CR Double-Crane Revenue in Hospital Injectable Drugs Business (2017-2022)

11.21.5 CR Double-Crane Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details